journal article·2022-08-24Open access

Biopolymer Nanoparticles for Nose-to-Brain Drug Delivery: A New Promising Approach for the Treatment of Neurological Diseases

Nicolò Montegiove, Eleonora Calzoni, Carla Emiliani, Alessio Cesaretti

Abstract

Diseases affecting the central nervous system (CNS) are among the most disabling and the most difficult to cure due to the presence of the blood–brain barrier (BBB) which represents an impediment from a therapeutic and diagnostic point of view as it limits the entry of most drugs. The use of biocompatible polymer nanoparticles (NPs) as vehicles for targeted drug delivery to the brain arouses increasing interest. However, the route of administration of these vectors remains critical as the drug must be delivered without being degraded to achieve a therapeutic effect. An innovative approach for the administration of drugs to the brain using polymeric carriers is represented by the nose-to-brain (NtB) route which involves the administration of the therapeutic molecule through the neuro-olfactory epithelium of the nasal mucosa. Nasal administration is a non-invasive approach that allows the rapid transport of the drug directly to the brain and minimizes its systemic exposure. To date, many studies involve the use of polymer NPs for the NtB transport of drugs to the brain for the treatment of a whole series of disabling neurological diseases for which, as of today, there is no cure. In this review, various types of biodegradable polymer NPs for drug delivery to the brain through the NtB route are discussed and particular attention is devoted to the treatment of neurological diseases such as Glioblastoma and neurodegenerative diseases.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Inhalation and Respiratory Drug Delivery · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, Biology and Biotechnology, Biochemistry and Molecular Biology Section, University of Perugia, Via del Giochetto, 06123 Perugia, Italy

Centro di Eccellenza sui Materiali Innovativi Nanostrutturati (CEMIN), University of Perugia, Via del Giochetto, 06123 Perugia, Italy

References (100+)

Show source-provided references
1. Central Nervous System Delivery of Molecules across the Blood–Brain Barrier10.1016/j.neuint.2020.104952 ↗
2. Modern Methods for Delivery of Drugs across the Blood–Brain Barrier10.1016/j.addr.2011.11.010 ↗
3. Calzoni, E., Cesaretti, A., Polchi, A., Di Michele, A., Tancini, B., and Emiliani, C. (2019). Biocompatible Polymer Nanoparticles for Drug Delivery Applications in Cancer and Neurodegenerative Disorder Therapies. J. Funct. Biomater., 10.10.3390/jfb10010004 ↗
4. Polchi, A., Magini, A., Mazuryk, J., Tancini, B., Gapiński, J., Patkowski, A., Giovagnoli, S., and Emiliani, C. (2016). Rapamycin Loaded Solid Lipid Nanoparticles as a New Tool to Deliver MTOR Inhibitors: Formulation and in Vitro Characterization. Nanomaterials, 6.10.3390/nano6050087 ↗
5. Solid Lipid Nanoparticles as a Drug Delivery System for the Treatment of Neurodegenerative Diseases10.1080/17425247.2016.1178237 ↗
6. Nanoparticles for Drug Delivery: The Need for Precision in Reporting Particle Size Parameters10.1016/j.ejpb.2007.08.001 ↗
7. Smart Polymers for the Controlled Delivery of Drugs—A Concise Overview10.1016/j.apsb.2014.02.005 ↗
8. Wells, C.M., Harris, M., Choi, L., Murali, V.P., Guerra, F.D., and Jennings, J.A. (2019). Stimuli-Responsive Drug Release from Smart Polymers. J. Funct. Biomater., 10.10.3390/jfb10030034 ↗
9. Khanal, S., Adhikari, U., Rijal, N.P., Bhattarai, S.R., Sankar, J., and Bhattarai, N. (2016). PH-Responsive PLGA Nanoparticle for Controlled Payload Delivery of Diclofenac Sodium. J. Funct. Biomater., 7.10.3390/jfb7030021 ↗
10. Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?10.3390/cancers5031020 ↗
11. Progress in Brain Targeting Drug Delivery System by Nasal Route10.1016/j.jconrel.2017.09.001 ↗
12. Progress and Perspectives of Brain-Targeting Lipid-Based Nanosystems via the Nasal Route in Alzheimer’s Disease10.1016/j.ejpb.2019.12.014 ↗
13. Nose-to-Brain Drug Delivery: An Update on Clinical Challenges and Progress towards Approval of Anti-Alzheimer Drugs10.1016/j.jconrel.2018.05.011 ↗
14. Pathophysiology of the Blood–Brain Barrier: Animal Models and Methods10.1016/S0070-2153(07)80007-X ↗
15. The Blood–Brain Barrier in Health and Chronic Neurodegenerative Disorders10.1016/j.neuron.2008.01.003 ↗
16. Drug Transport across the Blood–Brain Barrier10.1038/jcbfm.2012.126 ↗
17. Transport of Drugs across the Blood–Brain Barrier by Nanoparticles10.1016/j.jconrel.2011.08.017 ↗
18. Blood–Brain Barrier: From Physiology to Disease and Back10.1152/physrev.00050.2017 ↗
19. Singh, N., and Ecker, G.F. (2018). Insights into the Structure, Function, and Ligand Discovery of the Large Neutral Amino Acid Transporter 1, LAT1. Int. J. Mol. Sci., 19.10.3390/ijms19051278 ↗
20. Blood–Brain Barrier Active Efflux Transporters: ATP-Binding Cassette Gene Family10.1602/neurorx.2.1.86 ↗
21. Drug Resistance in Brain Diseases and the Role of Drug Efflux Transporters10.1038/nrn1728 ↗
22. Quantitative Targeted Absolute Proteomics of Human Blood–Brain Barrier Transporters and Receptors10.1111/j.1471-4159.2011.07208.x ↗
23. Gao, H., and Gao, X. (2019). 8-Efflux Pump Inhibition to Enhance Brain Targeting Delivery. Brain Targeted Drug Delivery System, Academic Press.10.1016/B978-0-12-814001-7.00018-4 ↗
24. PEGylated PLGA Nanoparticles As a Smart Carrier to Increase the Cellular Uptake of a Coumarin-Based Monoamine Oxidase B Inhibitor10.1021/acsami.8b17224 ↗
25. Architecture of the Paracellular Channels Formed by Claudins of the Blood–Brain Barrier Tight Junctions10.1111/nyas.13378 ↗
26. Brain-Specific Ultrastructure of Capillary Endothelial Glycocalyx and Its Possible Contribution for Blood Brain Barrier10.1038/s41598-018-35976-2 ↗
27. Into Rather Unexplored Terrain—Transcellular Transport across the Blood–Brain Barrier10.1002/glia.22960 ↗
28. Antibody Therapies in CNS Diseases10.1016/j.neuropharm.2016.03.014 ↗
29. Cationic Albumin-Conjugated Pegylated Nanoparticles as Novel Drug Carrier for Brain Delivery10.1016/j.jconrel.2005.03.027 ↗
30. Mechanisms of Clathrin-Mediated Endocytosis10.1038/nrm.2017.132 ↗
31. Developmental Changes in Transporter and Receptor Protein Expression Levels at the Rat Blood–Brain Barrier Based on Quantitative Targeted Absolute Proteomics10.1016/j.dmpk.2019.09.003 ↗
32. Wang, S., Meng, Y., Li, C., Qian, M., and Huang, R. (2016). Receptor-Mediated Drug Delivery Systems Targeting to Glioma. Nanomaterials, 6.10.3390/nano6010003 ↗
33. Crossing the Blood–Brain Barrier with Nanoparticles10.1016/j.jconrel.2017.12.015 ↗
34. Drug Delivery across the Blood–Brain Barrier: Recent Advances in the Use of Nanocarriers10.2217/nnm-2019-0367 ↗
35. The Blood–Brain Barrier: Physiology and Strategies for Drug Delivery10.1016/j.addr.2019.11.009 ↗
36. Nanoparticle Technology for Drug Delivery across the Blood–Brain Barrier10.1081/DDC-120001481 ↗
37. Nanoparticle-Mediated Brain Drug Delivery: Overcoming Blood–Brain Barrier to Treat Neurodegenerative Diseases10.1016/j.jconrel.2016.05.044 ↗
38. Nanoencapsulation Techniques for Food Bioactive Components: A Review10.1007/s11947-012-0944-0 ↗
39. Polymer Nanoparticles: Preparation Techniques and Size-Control Parameters10.1016/j.progpolymsci.2011.01.001 ↗
40. Nanotech Approaches to Drug Delivery and Imaging10.1016/S1359-6446(03)02903-9 ↗
41. Abstract 2065: Anti-FSHR Antibody Fab’ Fragment Conjugated Immunoliposomes Loaded with Cyclodextrin-Paclitaxel Complex for Improved in Vitro Efficacy on Ovarian Cancer Cells10.1158/1538-7445.AM2016-2065 ↗
42. Chapter One—Protein- and Peptide-Drug Conjugates: An Emerging Drug Delivery Technology10.1016/bs.apcsb.2014.11.001 ↗
43. A Review of the Formation and Classification of Amphiphilic Block Copolymer Nanoparticulate Structures: Micelles, Nanospheres, Nanocapsules and Polymersomes10.1016/j.ejpb.2006.11.009 ↗
44. Organic Spherical Nucleic Acids for the Transport of a NIR-II-Emitting Dye across the Blood–Brain Barrier10.1002/anie.202002312 ↗
45. Cell-Penetrating Peptides Transport Noncovalently Linked Thermally Activated Delayed Fluorescence Nanoparticles for Time-Resolved Luminescence Imaging10.1021/jacs.8b08438 ↗
46. Intravaginal Gene Silencing Using Biodegradable Polymer Nanoparticles Densely Loaded with Small-Interfering RNA10.1038/nmat2444 ↗
47. Inflammasome-Activating Nanoparticles as Modular Systems for Optimizing Vaccine Efficacy10.1016/j.vaccine.2009.03.034 ↗
48. Calzoni, E., Cesaretti, A., Montegiove, N., Di Michele, A., and Emiliani, C. (2021). Enhanced Stability of Long-Living Immobilized Recombinant β-d-N-Acetyl-Hexosaminidase A on Polylactic Acid (PLA) Films for Potential Biomedical Applications. J. Funct. Biomater., 12.10.3390/jfb12020032 ↗
49. Calzoni, E., Cesaretti, A., Montegiove, N., Di Michele, A., Pellegrino, R.M., and Emiliani, C. (2022). HexA-Enzyme Coated Polymer Nanoparticles for the Development of a Drug-Delivery System in the Treatment of Sandhoff Lysosomal Storage Disease. J. Funct. Biomater., 13.10.3390/jfb13020037 ↗
50. Poly Lactic-Co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier10.3390/polym3031377 ↗
52. Grumezescu, A.M. (2016). Chapter 10—Drug-Delivery Nanocarriers to Cross the Blood–Brain Barrier. Nanobiomaterials in Drug Delivery, William Andrew Publishing.
53. Recent Advances in Polymeric Transdermal Drug Delivery Systems10.1016/j.jconrel.2021.11.025 ↗
54. Polymeric Nanomedicines for Image-Guided Drug Delivery and Tumor-Targeted Combination Therapy10.1016/j.nantod.2010.05.001 ↗
55. Polymers in Drug Delivery—State of the Art and Future Trends10.1002/adem.201080088 ↗
56. Multifunctional Nanocarriers for Diagnostics, Drug Delivery and Targeted Treatment across Blood–Brain Barrier: Perspectives on Tracking and Neuroimaging10.1186/1743-8977-7-3 ↗
57. Hersh, A.M., Alomari, S., and Tyler, B.M. (2022). Crossing the Blood–Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology. Int. J. Mol. Sci., 23.10.3390/ijms23084153 ↗
58. Pathways for Small Molecule Delivery to the Central Nervous System across the Blood–Brain Barrier
59. Balancing Cationic and Hydrophobic Content of PEGylated SiRNA Polyplexes Enhances Endosome Escape, Stability, Blood Circulation Time, and Bioactivity in Vivo10.1021/nn403325f ↗
60. Nanoparticle Transport across the Blood Brain Barrier10.1080/21688370.2016.1153568 ↗
61. Targeting Therapeutics across the Blood Brain Barrier (BBB), Prerequisite towards Thrombolytic Therapy for Cerebrovascular Disorders—An Overview and Advancements10.1208/s12249-015-0287-z ↗
62. CNS Delivery via Adsorptive Transcytosis10.1208/s12248-008-9055-2 ↗
63. Current Advances in the Development of Novel Polymeric Nanoparticles for the Treatment of Neurodegenerative Diseases10.2217/nnm-2019-0443 ↗
64. Overcoming Blood–Brain Barrier Transport: Advances in Nanoparticle-Based Drug Delivery Strategies10.1016/j.mattod.2020.02.001 ↗
65. Adsorptive-Mediated Brain Delivery Systems10.2174/138920112803341851 ↗
66. Kristensen, M., Kucharz, K., Fernandes, E.F.A., Strømgaard, K., Nielsen, M.S., Helms, H.C.C., Bach, A., Tofte-Hansen, M.U., Garcia, B.I.A., and Lauritzen, M. (2020). Conjugation of Therapeutic PSD-95 Inhibitors to the Cell-Penetrating Peptide Tat Affects Blood–Brain Barrier Adherence, Uptake, and Permeation. Pharmaceutics, 12.10.3390/pharmaceutics12070661 ↗
67. A Novel Botulinum Toxin TAT-EGFP-HCS Fusion Protein Capable of Specific Delivery through the Blood–Brain Barrier to the Central Nervous System10.2174/1871527317666181011113215 ↗
68. Targeting Receptor-Mediated Transport for Delivery of Biologics across the Blood–Brain Barrier10.1146/annurev-pharmtox-010814-124852 ↗
69. Enabling Dual Cellular Destinations of Polymeric Nanoparticles for Treatment Following Partial Injury to the Central Nervous System10.1016/j.biomaterials.2015.10.001 ↗
70. Betzer, O., Shilo, M., Motiei, M., and Popovtzer, R. (2019, January 5). Insulin-Coated Gold Nanoparticles as an Effective Approach for Bypassing the Blood–Brain Barrier. Proceedings of the Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XVI, SPIE, San Francisco, CA, USA.10.1117/12.2510353 ↗
71. The Effect of Nanoparticle Size on the Ability to Cross the Blood–Brain Barrier: An in Vivo Study10.2217/nnm-2017-0022 ↗
72. Wagner, S., Zensi, A., Wien, S.L., Tschickardt, S.E., Maier, W., Vogel, T., Worek, F., Pietrzik, C.U., Kreuter, J., and von Briesen, H. (2012). Uptake Mechanism of ApoE-Modified Nanoparticles on Brain Capillary Endothelial Cells as a Blood–Brain Barrier Model. PLoS ONE, 7.10.1371/journal.pone.0032568 ↗
73. From Adsorption to Covalent Bonding: Apolipoprotein E Functionalization of Polymeric Nanoparticles for Drug Delivery Across the Blood–Brain Barrier10.1002/adtp.202000092 ↗
74. Characterization of Endocytosis of Transferrin-Coated PLGA Nanoparticles by the Blood–Brain Barrier10.1016/j.ijpharm.2009.04.035 ↗
75. Nanoparticulate Systems for Brain Delivery of Drugs10.1016/S0169-409X(00)00122-8 ↗
76. Brain-Targeted Delivery of Docetaxel by Glutathione-Coated Nanoparticles for Brain Cancer10.1208/s12249-014-0165-0 ↗
77. Biotin and Glutathione Targeting of Solid Nanoparticles to Cross Human Brain Endothelial Cells10.2174/1381612823666170727144450 ↗
78. Polyalkylcyanoacrylate Nanoparticles for Delivery of Drugs across the Blood–Brain Barrier10.1002/wnan.5 ↗
79. Systemic Delivery to Central Nervous System by Engineered PLGA Nanoparticles
80. Convection-Enhanced Delivery of Camptothecin-Loaded Polymer Nanoparticles for Treatment of Intracranial Tumors10.1007/s13346-010-0001-3 ↗
81. Polymeric Nanoparticles-Based Brain Delivery with Improved Therapeutic Efficacy of Ginkgolide B in Parkinson’s Disease10.2147/IJN.S272831 ↗
82. Guerrini, L., Alvarez-Puebla, R.A., and Pazos-Perez, N. (2018). Surface Modifications of Nanoparticles for Stability in Biological Fluids. Materials, 11.10.3390/ma11071154 ↗
83. Development and Evaluation of Polymer Nanoparticles for Oral Delivery of Estradiol to Rat Brain in a Model of Alzheimer’s Pathology10.1016/j.jconrel.2010.11.013 ↗
84. Comparable Intestinal and Hepatic First-Pass Effect of YL-IPA08 on the Bioavailability and Effective Brain Exposure, a Rapid Anti-PTSD and Anti-Depression Compound10.3389/fphar.2020.588127 ↗
85. The Nasal Approach to Delivering Treatment for Brain Diseases: An Anatomic, Physiologic, and Delivery Technology Overview10.4155/tde.14.41 ↗
86. Formulation and Device Design to Increase Nose to Brain Drug Delivery10.1016/j.jddst.2016.05.003 ↗
87. Bonferoni, M.C., Rossi, S., Sandri, G., Ferrari, F., Gavini, E., Rassu, G., and Giunchedi, P. (2019). Nanoemulsions for “Nose-to-Brain” Drug Delivery. Pharmaceutics, 11.10.3390/pharmaceutics11020084 ↗
88. Recent Progress in Nanocarriers for Direct Nose to Brain Drug Delivery10.1016/j.jddst.2021.102642 ↗
89. Intranasal Delivery of Biologics to the Central Nervous System10.1016/j.addr.2011.11.002 ↗
90. Intranasal Treatment of Central Nervous System Dysfunction in Humans10.1007/s11095-012-0915-1 ↗
91. Quantitative Analysis of the Olfactory Pathway for Drug Delivery to the Brain10.1016/0006-8993(95)00637-6 ↗
92. Delivery of 125I-NGF to the Brain via the Olfactory Route10.3109/10717549709051878 ↗
93. Therapeutic Efficacy of Intranasally Delivered Mesenchymal Stem Cells in a Rat Model of Parkinson Disease10.1089/rej.2010.1130 ↗
94. Viral Replication in Olfactory Receptor Neurons and Entry into the Olfactory Bulb and Braina10.1111/j.1749-6632.1998.tb10655.x ↗
95. Mechanism of Intranasal Drug Delivery Directly to the Brain10.1016/j.lfs.2017.12.025 ↗
96. Intranasal Mucoadhesive Microemulsions of Clonazepam: Preliminary Studies on Brain Targeting10.1002/jps.20480 ↗
97. Intranasal Delivery to the Central Nervous System: Mechanisms and Experimental Considerations10.1002/jps.21924 ↗
98. Transport of Drugs from the Nasal Cavity to the Central Nervous System10.1016/S0928-0987(00)00087-7 ↗
99. Direct Nose to Brain Drug Delivery via Integrated Nerve Pathways Bypassing the Blood–Brain Barrier: An Excellent Platform for Brain Targeting10.1517/17425247.2013.790887 ↗
100. Nanoparticles for Direct Nose-to-Brain Delivery of Drugs10.1016/j.ijpharm.2009.06.019 ↗